https://www.annovisbio.com/ 2025-10-01T07:36:19+00:00 1.00 https://www.annovisbio.com/about-us 2025-09-30T09:40:38+00:00 0.80 https://www.annovisbio.com/our-science 2025-09-30T09:40:36+00:00 0.80 https://www.annovisbio.com/pipeline 2025-09-30T09:40:37+00:00 0.80 https://www.annovisbio.com/patient-portal 2025-09-30T09:40:38+00:00 0.80 https://www.annovisbio.com/alzheimers-disease 2025-09-30T09:40:39+00:00 0.80 https://www.annovisbio.com/parkinsons-disease 2025-09-30T09:40:37+00:00 0.80 https://www.annovisbio.com/investors-relations 2025-09-30T09:38:02+00:00 0.80 https://www.annovisbio.com/sec-fillings 2025-09-30T12:58:59+00:00 0.80 https://www.annovisbio.com/faq 2025-09-30T09:40:37+00:00 0.80 https://www.annovisbio.com/press-release 2025-09-30T09:35:04+00:00 0.80 https://www.annovisbio.com/video-library 2025-09-30T09:40:38+00:00 0.80 https://www.annovisbio.com/media-library 2025-09-30T09:40:37+00:00 0.80 https://www.annovisbio.com/email-alerts 2025-09-30T09:40:37+00:00 0.80 https://www.annovisbio.com/contact-us 2025-09-30T09:40:38+00:00 0.80 https://www.annovisbio.com/press-release/annovis-appoints-mark-guerin-as-chief-financial-officer 2025-09-30T09:40:38+00:00 0.80 https://www.annovisbio.com/press-release/annovis-reports-peer-reviewed-publication-highlighting-pharmacokinetics-of-novel-crystal-buntanetap 2025-09-30T11:31:28+00:00 0.80 https://www.annovisbio.com/press-release/annovis-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference 2025-09-30T09:40:38+00:00 0.80 https://www.annovisbio.com/press-release/annovis-bio-announces-statistically-significant-phase-ii-iii-data-in-patients-with-early-alzheimers-disease 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/publications 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/expanded-access-policy 2025-10-01T07:14:14+00:00 0.64 https://www.annovisbio.com/quarterly-earnings 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/corporate-governance 2025-09-30T09:40:41+00:00 0.64 https://www.annovisbio.com/press-release/annovis-provides-corporate-updates-and-reports-second-quarter-2025-financial-results 2025-09-30T10:52:04+00:00 0.64 https://www.annovisbio.com/press-release/annovis-completes-full-patent-transfer-to-crystal-buntanetap 2025-09-30T09:40:41+00:00 0.64 https://www.annovisbio.com/press-release/annovis-to-attend-the-aaic-2025-with-four-poster-presentations 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/press-release/annovis-announces-nyse-acceptance-of-plan-to-regain-listing-compliance 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/press-release/annovis-to-host-webinar-and-live-q-a-on-june-24-2025 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/press-release/annovis-provides-corporate-updates-and-reports-first-quarter-2025-financial-results 2025-09-30T10:52:03+00:00 0.64 https://www.annovisbio.com/press-release/annovis-bio-appoints-hui-liu-as-director-of-biostatistics 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/press-release/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse 2025-09-30T09:40:41+00:00 0.64 https://www.annovisbio.com/press-release/annovis-to-attend-ad-pd-tm-2025-with-extensive-scientific-program 2025-09-30T09:40:41+00:00 0.64 https://www.annovisbio.com/press-release/annovis-provides-corporate-updates-and-reports-fourth-quarter-and-fiscal-year-2024-financial-results 2025-09-30T11:19:21+00:00 0.64 https://www.annovisbio.com/press-release/annovis-joins-experts-at-drug-development-summit-to-redefine-parkinsons-treatment 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/press-release/annovis-to-host-patients-live-forum-on-february-27-2025 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/press-release/annovis-to-present-at-oppenheimers-35th-annual-healthcare-life-sciences-conference 2025-09-30T09:40:41+00:00 0.64 https://www.annovisbio.com/press-release/annovis-announces-first-patients-entered-into-pivotal-phase-3-study-of-buntanetap-for-early-alzheimers-disease 2025-09-30T10:10:48+00:00 0.64 https://www.annovisbio.com/press-release/annovis-bio-inc-announces-pricing-of-21-million-public-offering-2 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/press-release/annovis-bio-inc-announces-proposed-public-offering-2 2025-09-30T09:40:41+00:00 0.64 https://www.annovisbio.com/press-release/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection 2025-09-30T09:40:41+00:00 0.64 https://www.annovisbio.com/press-release/fda-accepts-final-protocol-for-pivotal-phase-3-alzheimers-disease-study-streamlining-development-pathway 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/press-release/annovis-to-host-year-end-investor-webcast-on-december-11-2024 2025-09-30T09:40:41+00:00 0.64 https://www.annovisbio.com/press-release?ce54d9c0_page=2 2025-09-30T09:40:41+00:00 0.64 https://www.annovisbio.com/media-library/form-b-poster---aaic-2025 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/media-library/pk-poster-aaic2025 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/media-library/phase-3-ad-enrollment-poster-maccallum 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/media-library/design-phase3-poster-aaic-2025 2025-09-30T23:08:27+00:00 0.64 https://www.annovisbio.com/media-library/annovis-bio-brochure 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/media-library/biomarker-poster---ctad-2024 2025-09-30T12:21:55+00:00 0.64 https://www.annovisbio.com/media-library/efficacy-poster---ctad2024 2025-10-01T05:30:30+00:00 0.64 https://www.annovisbio.com/media-library/an-open-letter-from-maria-maccecchini-ph-d-ceo-of-annovis-bio 2025-09-30T09:40:40+00:00 0.64 https://www.annovisbio.com/press-release/annovis-invited-to-present-at-national-institute-on-aging-workshop-on-dementia-with-lewy-bodies-dlb 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-reports-third-quarter-financial-results-and-provides-business-update 2025-09-30T13:30:20+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-appoints-matthew-peterson-ph-d-as-senior-clinical-scientist 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-to-highlight-buntanetaps-alzheimers-research-progress-with-presentations-at-ctad-2024 2025-09-30T10:12:26+00:00 0.51 https://www.annovisbio.com/press-release/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas 2025-09-30T12:55:58+00:00 0.51 https://www.annovisbio.com/press-release/annovis-files-three-new-patents-for-combination-therapies-involving-buntanetap-trulicity-and-viagra 2025-10-01T07:14:16+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-nyse-anvs-to-present-at-h-c-wainwright-26th-annual-global-investment-conference 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-reports-second-quarter-financial-results-and-provides-business-update 2025-09-30T19:16:11+00:00 0.51 https://www.annovisbio.com/press-release/annovis-lead-compound-enhances-cognition-synergistically-with-glp-1-agonist 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-secures-u-s-patent-for-treatment-of-acute-traumatic-brain-injury-with-buntanetap 2025-09-30T09:40:42+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-receives-fda-approval-to-transition-to-new-crystal-form-of-buntanetap 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-welcomes-four-new-executives-to-strengthen-leadership-team 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-announces-new-data-from-phase-iii-parkinsons-study-highlighting-improvements-in-unified-parkinsons-disease-rating-scale-mds-updrs-and-cognition-after-treatment-with-buntanetap 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-files-provisional-patent-for-new-manufacturing-process-of-crystalline-form-of-buntanetap 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-files-patent-for-new-composition-of-matter-for-buntanetap 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-inc-nyse-anvs-schedules-investor-webcast-to-discuss-parkinsons-disease-data 2025-09-30T09:40:44+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-highlights-new-alzheimers-data-at-the-alzheimers-association-international-conference-r-2024 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bios-buntanetap-found-safe-and-effective-in-high-risk-alzheimers-patients 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-inc-nyse-anvs-schedules-investor-webcast 2025-09-30T09:40:44+00:00 0.51 https://www.annovisbio.com/press-release/annovis-announces-new-publication-in-a-peer-reviewed-journal 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-provides-corporate-updates-and-announces-first-quarter-2024-financial-results 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-announces-unblinding-of-the-buntanetap-phase-iii-data-in-parkinsons-disease 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release?ce54d9c0_page=1 2025-10-01T07:14:16+00:00 0.51 https://www.annovisbio.com/press-release?ce54d9c0_page=3 2025-09-30T09:40:43+00:00 0.51 https://www.annovisbio.com/press-release/annovis-bio-ceo-maria-maccecchini-issues-letter-to-stockholders 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-provides-corporate-updates-and-reports-fourth-quarter-and-full-year-2023-financial-results 2025-09-30T10:52:03+00:00 0.41 https://www.annovisbio.com/press-release/annovis-announces-publication-that-supports-understanding-of-buntanetaps-mechanism-of-action-in-humans 2025-09-30T15:50:09+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-provides-data-announcement-update-for-the-phase-ii-iii-study-of-buntanetap-in-alzheimers-disease 2025-09-30T09:40:44+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-participation-in-forum-discussion-at-ad-pd-tm-2024 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-last-patient-last-visit-in-the-phase-ii-iii-study-of-buntanetap-in-alzheimers-disease 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-the-filing-of-new-patent-application-for-treatment-of-mental-illnesses-expanding-the-companys-portfolio 2025-09-30T09:40:46+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-refines-timeline-for-parkinsons-phase-iii-study-data-announcement 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-to-participate-in-the-139th-yale-ceo-summit 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-last-patient-last-visit-in-the-phase-iii-study-of-buntanetap-in-parkinsons-disease 2025-09-30T20:26:09+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-appoints-andrew-walsh-as-vice-president-finance 2025-09-30T22:08:47+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-full-enrollment-of-its-phase-ii-iii-alzheimers-disease-trial-exceeding-original-projections 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-third-quarter-2023-financial-results-and-provides-corporate-update 2025-09-30T09:40:46+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-measures-novel-biomarkers-in-plasma-of-parkinsons-patients 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-pricing-of-7-5-million-public-offering 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-receives-positive-recommendation-to-continue-phase-2-3-trial-of-buntanetap-for-alzheimers-disease-patients-from-the-independent-data-and-safety-monitoring-board-dsmb 2025-09-30T09:40:46+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-launch-of-proposed-public-offering 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-showcases-promising-progress-in-novel-drug-development-at-the-2023-clinical-trials-on-alzheimers-disease-conference 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-positive-interim-independent-analysis-for-statistical-power-in-its-alzheimers-study 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-second-quarter-2023-financial-results-and-provides-corporate-update 2025-09-30T09:40:46+00:00 0.41 https://www.annovisbio.com/press-release/continued-positive-performance-of-novel-drug-development-by-annovis-bio-presented-at-2023-alzheimers-association-international-conference 2025-09-30T09:40:45+00:00 0.41 https://www.annovisbio.com/press-release?ce54d9c0_page=4 2025-09-30T09:40:44+00:00 0.41 https://www.annovisbio.com/press-release/annovis-bio-announces-the-filing-of-a-groundbreaking-patent 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-receives-excellent-safety-rating-and-positive-recommendation-to-continue-phase-iii-trial-of-buntanetap-for-parkinsons-disease-patients-from-the-independent-data-and-safety-monitoring-board-dsmb 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-completion-of-phase-iii-parkinsons-disease-treatment-enrollment-at-record-pace 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-to-participate-at-the-benzinga-global-small-cap-conference-and-present-to-investors-on-may-13-2021 2025-09-30T09:40:46+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-first-quarter-2023-financial-results-and-provides-corporate-update 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-issuance-of-u-s-patent-covering-the-use-of-lead-drug-candidate-buntanetap-for-prevention-or-treatment-of-disease-states-due-to-metal-dis-homeostasis-in-healthy-or-sick-humans 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-provides-updated-webcast-link-and-dial-in-information-for-todays-r-d-webcast 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-update-on-recruitment-into-its-phase-2-3-alzheimers-study-and-upcoming-r-d-webcast 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-to-hold-live-webcast-to-review-alzheimers-disease-and-parkinsons-disease-clinical-programs 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-raises-aggregate-gross-proceeds-of-approximately-8-7-million 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update 2025-09-30T09:40:48+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-two-presentations-at-the-ad-pd-tm-2023-international-conference-on-alzheimers-and-parkinsons-diseases 2025-10-01T07:14:19+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-approval-for-european-union-clinical-trial-sites-for-the-phase-3-study-of-buntanetap-for-the-treatment-of-parkinsons-disease 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-filing-of-patent-covering-the-administration-of-buntanetap-and-its-analogues-for-the-treatment-of-mental-illnesses 2025-09-30T19:05:50+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-patient-enrollment-update-for-phase-3-study-of-buntanetap-for-the-treatment-of-parkinsons-disease 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-new-appointments-to-strengthen-its-senior-leadership-team 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-third-quarter-2022-results-and-provides-corporate-update 2025-09-30T09:40:48+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-2022-thinkequity-investor-conference 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-publication-of-phase-2a-clinical-data-in-the-journal-of-prevention-of-alzheimers-disease 2025-09-30T09:40:46+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-fda-authorization-to-proceed-with-phase-2-3-trial-for-buntanetap-in-alzheimers-disease 2025-10-01T02:37:10+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference 2025-09-30T09:40:47+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bio-announces-publication-of-patents-covering-the-treatment-of-amyloid-lateral-sclerosis-huntingtons-disease-and-prion-diseases 2025-09-30T09:40:46+00:00 0.33 https://www.annovisbio.com/press-release?ce54d9c0_page=5 2025-09-30T09:40:46+00:00 0.33 https://www.annovisbio.com/press-release/annovis-bios-ceo-maria-maccecchini-issues-letter-to-stockholders 2025-10-01T05:30:33+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-appoints-henry-hagopian-iii-as-chief-financial-officer 2025-09-30T18:50:21+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-announces-first-patient-dosed-in-phase-3-trial-in-patients-with-early-parkinsons-disease 2025-09-30T16:17:04+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-announces-second-quarter-2022-results-and-provides-corporate-update 2025-09-30T18:55:54+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-to-participate-on-alzheimers-association-international-conference-panel 2025-09-30T12:28:36+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-alzheimers-association-international-conference 2025-10-01T05:30:34+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-announces-positive-fda-notice-for-buntanetap-phase-3-clinical-trial-in-parkinsons-disease 2025-09-30T10:12:26+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-submits-an-international-patent-application-to-cover-the-treatment-of-neurological-injuries-caused-by-infections 2025-09-30T18:26:51+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-announces-publication-of-anvs401-mechanism-of-action-in-peer-reviewed-pharmaceutics 2025-09-30T13:42:25+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-announces-transfer-of-listing-to-the-new-york-stock-exchange 2025-09-30T10:17:40+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-presented-at-the-14th-clinical-trials-on-alzheimers-disease-conference 2025-10-01T05:30:33+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-presents-poster-on-mechanism-of-action-at-the-14th-clinical-trials-on-alzheimers-disease-ctad-conference 2025-09-30T18:37:56+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-14th-clinical-trials-on-alzheimers-disease-ctad-conference 2025-09-30T20:45:44+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-announces-positive-phase-2-efficacy-data-for-the-treatment-of-parkinsons-disease 2025-09-30T11:37:32+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-cantor-global-healthcare-conference 2025-10-01T05:30:34+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference 2025-10-01T05:30:33+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-interview-to-air-on-bloomberg-u-s-on-the-redchip-money-report-r 2025-10-01T07:36:40+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-biomarkers-for-alzheimers-disease-summit-2021 2025-10-01T05:30:33+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-completes-dosing-of-parkinsons-disease-patients-with-anvs401-in-phase-2a-clinical-trial 2025-09-30T16:54:10+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-pleased-by-positive-interim-results-from-ongoing-phase-ii-clinical-trials-of-anvs401-posiphen-for-the-treatment-of-alzheimers-disease-and-parkinsons-disease 2025-09-30T10:10:12+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-presents-new-clinical-and-biomarker-data-at-2021-alzheimers-association-international-conference 2025-10-01T05:30:34+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-to-present-new-data-at-2021-alzheimers-association-international-conference 2025-10-01T05:30:33+00:00 0.26 https://www.annovisbio.com/press-release?ce54d9c0_page=6 2025-10-01T05:30:34+00:00 0.26 https://www.annovisbio.com/press-release/annovis-bio-reports-positive-safety-data-from-its-phase-2-alzheimers-study 2025-09-30T14:42:05+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-to-present-data-at-alzheimers-association-international-conference-2021-highlighting-positive-clinical-outcomes-from-its-two-phase-2a-trials 2025-10-01T05:30:34+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-ceo-wins-2021-pact-enterprise-award-for-life-sciences-and-healthcare-ceo 2025-10-01T05:30:34+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-ceo-selected-as-a-finalist-in-the-2021-pact-enterprise-awards 2025-09-30T14:58:06+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-expands-potential-application-of-anvs401-to-infectious-diseases-with-new-preclinical-study 2025-10-01T07:36:43+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-jefferies-virtual-healthcare-conference-2021 2025-10-01T05:30:34+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bios-anvs401-improves-speed-and-accuracy-in-alzheimers-and-in-parkinsons-patients 2025-10-01T07:36:44+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-engages-global-executive-search-leader-spencer-stuart-to-expand-its-board-and-management-team 2025-09-30T22:47:32+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-inc-announces-closing-of-50-million-public-offering 2025-09-30T19:06:52+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-inc-announces-pricing-of-public-offering 2025-09-30T10:11:44+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-announces-positive-phase-2-data---anvs401-improves-cognition-in-alzheimers-disease---patients-cognition-improved-3-3-points-on-adas-cog11 2025-09-30T11:53:01+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-inc-announces-proposed-public-offering-of-common-stock 2025-10-01T07:14:22+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-announces-positive-phase-2-data-anvs401-significantly-lowers-inflammatory-markers-in-parkinsons-patients 2025-09-30T14:42:05+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-to-participate-in-alzheimer-disease-panel-presented-by-maxim-group-llc-and-hosted-by-m-vest-on-may-26th-2021 2025-09-30T19:43:21+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-appoints-accomplished-neuroscientist-dr-cheng-fang-as-vp-of-research 2025-09-30T19:41:00+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-files-for-fda-orphan-drug-designation-for-anvs401-for-the-treatment-of-alzheimers-disease-in-persons-with-down-syndrome 2025-09-30T14:27:37+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-to-ring-closing-bell-at-the-new-york-stock-exchange 2025-09-30T13:39:45+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-receives-us-patent-for-method-of-treating-frontotemporal-dementia-and-chronic-traumatic-encephalopathy 2025-09-30T18:33:36+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-to-study-potential-of-anvs401-to-normalize-brain-development-in-down-syndrome 2025-09-30T09:42:17+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-appoints-reid-mccarthy-to-board-and-to-role-of-audit-committee-chairman 2025-09-30T23:04:20+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-presenting-at-m-vest-and-maxim-group-inaugural-emerging-growth-virtual-conference 2025-09-30T16:44:41+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-announces-positive-phase-2-data---interim-data-shows-anvs401-improves-speed-and-coordination-in-parkinsons-patients 2025-09-30T14:42:05+00:00 0.21 https://www.annovisbio.com/press-release?ce54d9c0_page=7 2025-10-01T05:30:34+00:00 0.21 https://www.annovisbio.com/press-release/annovis-bio-inc-to-present-at-the-q1-virtual-investor-summit 2025-10-01T07:14:23+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-signs-gmp-manufacturing-agreement-to-support-planned-late--stage-studies 2025-09-30T18:28:02+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-receives-japanese-patent-for-the-treatment-of-acute-brain-or-nerve-injury 2025-09-30T14:53:41+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-h-c-wainwright-global-life-sciences-conference 2025-09-30T22:43:21+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-bio-ceo-investor-digital-conference 2025-09-30T15:15:53+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-receives-european-patent-for-method-of-treating-acute-nerve-and-brain-insults 2025-09-30T11:36:15+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bios-lead-candidate-anvs401-improves-cognitive-and-functional-outcomes-in-stroke-mice-study 2025-09-30T16:44:58+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-h-c-wainwright-bioconnect-2021-conference 2025-10-01T07:14:22+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-showcases-its-unique-approach-to-alzheimers-at-the-new-york-academy-of-sciences 2025-10-01T07:14:23+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-benzinga-global-small-cap-conference-on-december-8-2020 2025-10-01T07:14:22+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-new-york-academy-of-sciences-alzheimers-disease-therapeutics-alternatives-to-amyloid-2020-virtual-conference 2025-09-30T13:20:58+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-to-participate-in-a-g-p-s-virtual-healthcare-symposium 2025-10-01T02:35:39+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases 2025-09-30T14:13:49+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-ceo-to-present-at-meridian-clinical-trials-summit 2025-09-30T19:43:36+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-resumes-treatment-of-patients-in-ongoing-phase-2a-study-in-alzheimers-disease-after-covid-related-delay 2025-09-30T16:23:38+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-ceo-receives-2020-smart-business-dealmaker-award 2025-10-01T07:14:22+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-ceo-participates-in-roundtable-discussion-at-the-financial-times-outstanding-directors-exchange-and-panel-discussion-at-the-angel-venture-fair 2025-10-01T03:46:12+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-provides-third-quarter-2020-and-year-to-date-business-highlights 2025-10-01T07:14:22+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-2020-bio-investor-forum 2025-09-30T13:21:00+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-demonstrates-improved-axonal-transport-in-nerve-cells-and-brain-of-down-syndrome-mice-an-animal-model-of-alzheimers-disease 2025-10-01T07:14:23+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-begins-treatment-of-first-patients-in-its-phase-2a-alzheimers-and-parkinsons-trial 2025-10-01T07:14:23+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-actively-recruiting-patients-for-its-phase-2a-trials-in-alzheimers-and-parkinsons-diseases 2025-10-01T07:14:23+00:00 0.17 https://www.annovisbio.com/press-release?ce54d9c0_page=8 2025-10-01T01:02:58+00:00 0.17 https://www.annovisbio.com/press-release/annovis-bio-ceo-appears-on-executive-leaders-radio-program 2025-10-01T07:14:24+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-ceo-to-present-the-companys-novel-approach-to-treating-parkinsons-disease-at-university-of-pennsylvania 2025-09-30T22:58:21+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-receives-institutional-review-board-approval-to-initiate-15-site-phase-2-study-in-68-parkinsons-and-alzheimers-patients 2025-09-30T14:01:15+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-announces-positive-results-from-nih-funded-chronic-toxicology-study 2025-09-30T22:25:22+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-to-present-at-the-june-2020-virtual-summer-investor-summit 2025-10-01T04:26:08+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-issued-european-patent-for-method-of-treating-alzheimers-disease-with-anvs401 2025-09-30T11:39:39+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-2020-annual-meeting-of-stockholders-to-be-held-on-june-3-2020 2025-09-30T15:21:23+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-files-patent-application-for-method-of-inhibiting-preventing-or-treating-neurological-injuries-due-to-viral-and-other-infections-including-covid-19 2025-09-30T18:49:09+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3 2025-09-30T19:38:03+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-announces-plans-for-a-new-phase-ii-clinical-trial-to-treat-68-parkinsons-and-alzheimers-patients 2025-10-01T07:14:24+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-publishes-results-of-alzheimers-and-parkinsons-animal-studies 2025-09-30T11:30:39+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-to-hold-investor-webinar-and-q-a-session-with-ceo-on-april-14 2025-09-30T20:54:32+00:00 0.13 https://www.annovisbio.com/press-release/annovis-awarded-1-7-million-nih-grant-for-anvs401-chronic-toxicology-studies 2025-09-30T14:13:49+00:00 0.13 https://www.annovisbio.com/press-release/annovis-issued-patent-for-method-of-treating-parkinsons-disease-and-other-lewy-body-diseases 2025-09-30T14:32:42+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-announces-update-on-phase-ii-clinical-trial-for-alzheimers-disease 2025-10-01T03:40:06+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares 2025-09-30T19:06:30+00:00 0.13 https://www.annovisbio.com/press-release/annovis-bio-announces-pricing-of-initial-public-offering 2025-10-01T02:31:44+00:00 0.13